Health Investment Returns: Harnessing Health as...

By João L. Carapinha

November 18, 2025

Health as a Strategic Economic Imperative A country's enduring strength stems not solely from military or industrial resources but from the vitality and productivity of its populace. A recen...
Promising Advances in TNBC Treatment: Sacituzumab Govitecan in First-Line The...
Interchangeable Biosimilar Approval: FDA Greenlights Poherdy as First to Perjeta
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost T...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
FDA Cancer Trial Guidelines: Prioritizing Overall Survival for Patient-Center...
Keytruda Lung Cancer Treatment: Long-Term Survival Gains in NSCLC
Promising PSMA-Targeted Therapy Delays Prostate Cancer Progression
Johnson & Johnson Advances Solid Tumor Research at ESMO 2025 with Promis...
Colorectal Cancer Markers: Discovering Region-Specific Drivers for Precision ...
Tukysa Breast Cancer Therapy Boosts Progression-Free Survival in Advanced Cases
Datroway TNBC Therapy: Transforming First-Line Treatment for Metastatic Tripl...
Lurbinectedin SCLC Therapy: FDA Approval and Its Economic Implications